Literature DB >> 12231494

Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit.

Ghulam Saydain1, Ashiq Islam, Bekele Afessa, Jay H Ryu, John P Scott, Steve G Peters.   

Abstract

This retrospective study describes the clinical course of 38 patients with idiopathic pulmonary fibrosis (IPF) admitted to the intensive care unit (ICU). There were 25 males and 13 females who were the mean age of 68.3 +/- 11.5 years. Twenty patients were on corticosteroids at the time of admission to the hospital, and 24 had been on home oxygen therapy. The most common reason for ICU admission was respiratory failure. The Acute Physiology and Chronic Health Evaluation III-predicted ICU and hospital mortality rates were 12% and 26%, whereas the actual ICU and hospital mortality rates were 45% and 61%, respectively. We did not find significant differences in pulmonary function or echocardiogram findings between survivors and nonsurvivors. Mechanical ventilation was used in 19 patients (50%). Sepsis developed in nine patients. Multiple organ failure developed in 14% of the survivors and in 43% of the nonsurvivors (p = 0.14). Ninety-two percent of the hospital survivors died at a median of 2 months after discharge. These findings suggest that patients with IPF admitted to the ICU have poor short- and long-term prognosis. Patients with IPF and their families should be informed about the overall outlook when they make decisions about life support and ICU care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12231494     DOI: 10.1164/rccm.2104038

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease.

Authors:  Evans R Fernández-Pérez; Murat Yilmaz; Hussam Jenad; Craig E Daniels; Jay H Ryu; Rolf D Hubmayr; Ognjen Gajic
Journal:  Chest       Date:  2007-11-07       Impact factor: 9.410

Review 2.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

3.  Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2009-04-10       Impact factor: 21.405

4.  Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2.

Authors:  Koji Kuronuma; Hiroaki Mitsuzawa; Katsuyuki Takeda; Chiaki Nishitani; Edward D Chan; Yoshio Kuroki; Mari Nakamura; Dennis R Voelker
Journal:  J Biol Chem       Date:  2009-07-07       Impact factor: 5.157

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

6.  Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography.

Authors:  Hidemi Suzuki; Yasuo Sekine; Shigetoshi Yoshida; Makoto Suzuki; Kiyoshi Shibuya; Yoko Yonemori; Kenzo Hiroshima; Yukio Nakatani; Satoko Mizuno; Yuichi Takiguchi; Ichiro Yoshino
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

7.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

8.  Transforming growth factor β1 alters the 3'-UTR of mRNA to promote lung fibrosis.

Authors:  Junsuk Ko; Tingting Mills; Jingjing Huang; Ning-Yuan Chen; Tinne C J Mertens; Scott D Collum; Garam Lee; Yu Xiang; Leng Han; Yang Zhou; Chun Geun Lee; Jack A Elias; Soma S K Jyothula; Keshava Rajagopal; Harry Karmouty-Quintana; Michael R Blackburn
Journal:  J Biol Chem       Date:  2019-09-05       Impact factor: 5.157

Review 9.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

10.  Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease.

Authors:  Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin
Journal:  Chest       Date:  2018-01-17       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.